You are hereBiocon

Biocon


Opportunity for Senior Role in -Injectables / Fill Finish Manufacturing in Biocon

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, it offers novel therapies on a platform of affordable innovation.
Biocon together with group companies employs more than 2500 employees with approxmimately Rs 1,000 crore turnover and is expected to grow further during the current financial year.

Post: Senior Role in -Injectables / Fill Finish Manufacturing


Biocon's Earnings Surge in Q1 FY16

(Business Wire India); Biocon Ltd, Asia's premier biopharmaceuticals company, announced today that it has delivered a strong consolidated financial performance for Q1 FY16.


Biocon chairman got 2nd Rank in 'Medicine Maker Power List 2015'

Biocon’s chairman and managing director Kiran Mazumdar-Shaw, got  2nd rank in ‘The Medicine Maker Power List' 2015, an index of the 100 most influential people across the globe in the field of medicine. The top 5 in ‘The Medicine Maker Power List’ are: Anthony Fauci, director, National Institute of Allergy and Infectious Diseases, USA, Kiran Mazumdar-Shaw, chairman & managing director, Biocon, Sir Andrew Witty, chief executive officer, GlaxoSmithKline, Arthur D. Levinson, chief executive officer, Calico and Heather Bresch, chief executive officer of Mylan.


Biocon's net profit pushes by Exceptional items over 78% in Q4

Biocon, a leading innovation-led bio-pharmaceutical company, has announced satisfactory financial performance during the fourth quarter ended March 2014. Its consolidated net profit, after exceptional income of Rs. 105 crore on account of sale of Syngene shares, increased by 78.2 per cent to Rs. 201.54 crore from Rs. 113.08 crore in the corresponding period of last year. Operating profit jumped 4.7 percent year-on-year to Rs 202 crore for the quarter ended March 2015 from Rs 193 crore in the same quarter last year.Profit before tax and exceptional income also improved by only 4 per cent to Rs. 143.54 crore from Rs. 138.06 crore. EPS moved up to Rs. 10.08 from Rs. 5.76 crore.  Its consolidated net sales increased by 14.9 per cent to Rs. 830.38 crore during the fourth quarter from Rs. 722.59 crore in the same period of last year. Its pharma sales increased by 10.8 per cent to Rs. 594.91 crore from Rs. 536.77 crore and that of contract research & manufacturing services improved by 27.7 per cent to Rs. 248.92 crore from Rs. 194.90 crore.


Biocon's CRO arm Syngene seeks approval for IPO, files DRHP; offer allows Biocon to monetize its shareholding in Syngene

(Business Wire India); Biocon Ltd, Asia's premier biopharmaceuticals company, today announced that its Contract Research subsidiary Syngene International Ltd (“Syngene”) has filed the Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) on April 22, 2015, seeking approval for an Initial Public Offering (IPO). This is an offer for sale (OFS) by Biocon of a part of its shareholding in Syngene. Biocon along with its subsidiary Biocon Research Limited (BRL) currently holds an 84.5% equity stake in Syngene.


Biocon Expands its Strategic Partnership with CytoSorbents for CytoSorb® to Treat SIRS and Cardiac Surgery Patients

(3rd November, 2014; Business Wire India); Biocon Ltd, Asia's premier biopharmaceuticals company, and U.S.-based CytoSorbents Corporation (OTCQB: CTSO) announced today that they have expanded the scope of their strategic partnership for CytoSorbents’ CytoSorb® cytokine reduction therapy to treat patients experiencing severe whole body inflammation, often called a Systemic Inflammatory Response Syndrome (SIRS).  SIRS is caused by a wide range of life-threatening conditions seen in the intensive care unit and can also be caused by surgical interventions, particularly cardiac surgery.


Walk in interview for Jr.Executive/Executive/Sr. Executive in Biocon

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, it offers novel therapies on a platform of affordable innovation.
Biocon together with group companies employs more than 2500 employees with approxmimately Rs 1,000 crore turnover and is expected to grow further during the current financial year.

We are looking for skilled and dynamic experienced professionals for our (API, Parenteral and Biologics) facilities in Bangalore.

Post: Jr.Executive/Executive/Sr. Executive


Job for Senior Executive Regulatory in Biocon

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, it offers novel therapies on a platform of affordable innovation.
Biocon together with group companies employs more than 2500 employees with approxmimately Rs 1,000 crore turnover and is expected to grow further during the current financial year.

Post: Senior Executive Regulatory


Walk in interview for B.Pharm, B.Sc, M.Pharm @ Biocon | Production-Fill Finish department (Experience candidates only)

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, it offers novel therapies on a platform of affordable innovation.
Biocon together with group companies employs more than 2500 employees with approxmimately Rs 1,000 crore turnover and is expected to grow further during the current financial year.

Post: Jr.Executive/Executive/Sr. Executive


Walk in @ Biocon for Production in MAbs, Fill Finish, Fermentation, GPP

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, it offers novel therapies on a platform of affordable innovation.
Biocon together with group companies employs more than 2500 employees with approxmimately Rs 1,000 crore turnover and is expected to grow further during the current financial year.

Post: Junior Executive/Executive/Senior Executive